• High Profile Publications

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

Authors: Nicholas I Paton, Joseph Musaazi, Cissy Kityo, Stephen Walimbwa, Anne Hoppe, Apolo Balyegisawa, Jesca Asienzo, Arvind Kaimal, Grace Mirembe, Abbas Lugemwa, Gilbert Ategeka, Margaret Borok, Henry Mugerwa, Abraham Siika, Eva Laker A Odongpiny, Barbara Castelnuovo, Agnes Kiragga, Andrew Kambugu; NADIA Trial Team

Journal: The lancet. HIV. 2022 Jun;9(6):e381-e393.

DOI: 10.1016/S2352-3018(22)00092-3

Notable Achievements

High Profile Publications

Adjunctive pascolizumab in rifampicin-susceptible pulmonary tuberculosis: proof-of-concept, partially-randomised, double-blind, placebo-controlled, dose-escalation trial

Authors: Nicholas I Paton, Meera Gurumurthy, Qingshu Lu, Francesca Leek, …

High Profile Publications

Short-chain fatty acids of various lengths differentially inhibit Klebsiella pneumoniae and Enterobacteriaceae species

Authors: Kai Chirng Chang, Niranjan Nagarajan, Yunn-Hwen Gan Journal: mSphere. …

High Profile Publications

Updated epithelial barrier dysfunction in chronic rhinosinusitis: Targeting pathophysiology and treatment response of tight junctions

Authors: Zhi-Qun Huang, Jing Liu, Li-Ying Sun, Hsiao Hui Ong, …

Infectious Diseases Translational Research Programme

© National University of Singapore. All Rights Reserved.